Similar articles

• Estimating the burden of serogroup C meningococcal disease in England and Wales.

  Davison KL, Ramsay ME, Crowcroft NS, Lieftucht A, Kaczmarski EB, Trotter CL, Gungabissoon U, Begg NT. Davison KL, et al. Commun Dis Public Health. 2002 Sep;5(3):213-9. Commun Dis Public Health. 2002. PMID: 12434691
• Meningococcal vaccines: advances but new questions?

  Tapsall J. Tapsall J. J Paediatr Child Health. 2001 Oct;37(5):S1-2. doi: 10.1046/j.1440-1754.2001.00733.x. J Paediatr Child Health. 2001. PMID: 11885730 No abstract available.
• Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines.

  Diggle MA, Clarke SC. Diggle MA, et al. J Clin Microbiol. 2005 Sep;43(9):4649-53. doi: 10.1128/JCM.43.9.4649-4653.2005. J Clin Microbiol. 2005. PMID: 16145121 Free PMC article.
• Challenges and opportunities for meningococcal vaccination in the developing world.

  Shaker R, Fayad D, Dbaibo G. Shaker R, et al. Hum Vaccin Immunother. 2018 May 4;14(5):1084-1097. doi: 10.1080/21645515.2018.1434463. Epub 2018 Feb 23. Hum Vaccin Immunother. 2018. PMID: 29393729 Free PMC article. Review.
• Evolving meningococcal immunization strategies.

  Sáfadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R; Global Meningococcal Initiative. Sáfadi MA, et al. Expert Rev Vaccines. 2015 Apr;14(4):505-17. doi: 10.1586/14760584.2015.979799. Epub 2014 Dec 10. Expert Rev Vaccines. 2015. PMID: 25494168 Review.